Sugammadex + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
General Surgery
Conditions
General Surgery
Trial Timeline
Jun 1, 2016 → Dec 1, 2019
NCT ID
NCT02728726About Sugammadex + Placebo
Sugammadex + Placebo is a approved stage product being developed by Merck for General Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT02728726. Target conditions include General Surgery.
What happened to similar drugs?
5 of 20 similar drugs in General Surgery were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02728726 | Approved | Completed |
| NCT02028065 | Phase 1 | Completed |
| NCT00591409 | Phase 2 | Completed |
| NCT00379613 | Phase 2 | Completed |
Competing Products
20 competing products in General Surgery